SPLV vs XBI
Invesco S&P 500 Low Volatility ETF vs SPDR S&P Biotech ETF
- • SPLV has the lower expense ratio at 0.25% vs 0.35% for XBI.
- • SPLV pays a higher dividend yield (2.16%).
Side-by-side metrics
| Metric | SPLV | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.25% | 0.35% |
Dividend yield Trailing 12-month yield. | 2.16% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $7.57B | $10.92B |
YTD return | 11.04% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.30 | 1.01 |
P/E ratio | 19.19 | — |
Last price | $77.85 | $156.41 |
Inception | — | — |
Issuer | Invesco | State Street |
SPLV top holdings
| BRK-B | Berkshire Hathaway Inc Class B | 1.43% |
| WEC | WEC Energy Group Inc | 1.34% |
| DUK | Duke Energy Corp | 1.30% |
| EVRG | Evergy Inc | 1.28% |
| CNP | CenterPoint Energy Inc | 1.26% |
| ATO | Atmos Energy Corp | 1.25% |
| LNT | Alliant Energy Corp | 1.25% |
| PNW | Pinnacle West Capital Corp | 1.25% |
| FE | FirstEnergy Corp | 1.24% |
| ED | Consolidated Edison Inc | 1.23% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About SPLV
SPLV (Invesco S&P 500 Low Volatility ETF) is 100 lowest-volatility S&P 500 stocks. Managed by Invesco, the fund carries $7.6B in assets under management, an expense ratio of 0.25%, a dividend yield of 2.16%. Its largest holding is Berkshire Hathaway Inc Class B (BRK-B), which represents 1.4% of the portfolio. Real Estate is the fund's largest sector exposure at 16.1%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.